Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

Bibliographic Details
Main Authors: M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, Arlene Naranjo, Mitchell B. Diccianni, Sheena C. Tenney, Malcolm Smith, Karen S. Messer, Robert Seeger, C. Patrick Reynolds, L. Mary Smith, Barry L. Shulkin, Marguerite Parisi, John M. Maris, Julie R. Park, Paul M. Sondel, Alice L. Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Immunology
Subjects:
neuroblastoma
immunotherapy
anti-GD2 chimeric antibody
cytokines
safety
cytokine biomarkers
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01641/full

Similar Items

Similar Items